Scienture (SCNX) 10-Q 7 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-39199
Entity Registrant Name	TRxADE HEALTH, INC.
Entity Central Index Key	0001382574
Entity Tax Identification Number	46-3673928
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2420 Brunello Trace
Entity Address, City or Town	Lutz
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33558
City Area Code	(800)
Local Phone Number	261-0281
Title of 12(b) Security	Common Stock, $0.00001 Par Value Per Share
Trading Symbol	MEDS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,318,708

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash	$ 321,715	$ 3,122,578
Accounts receivable, net	850,306	978,973
Inventory	75,950	56,279
Prepaid assets	249,785	216,414
Other receivable	875,250
Total Current Assets	2,373,006	4,374,244
Property plant and equipment, net	68,036	98,751
Intangible assets and capitalized software, net	1,099,002
Deposits	49,031	60,136
Operating lease right-of-use assets	1,100,186	1,233,033
Total Assets	4,689,261	5,766,164
Current Liabilities
Accounts payable	744,412	477,028
Accrued liabilities	312,077	270,437
Other current liabilities	105,926
Contingent funding liabilities	542,143
Current portion lease liabilities	190,127	178,561
Notes payable— related party	166,667
Total Current liabilities	2,061,352	926,026
Long Term Liabilities
Other long-term liabilities — leases	937,998	1,069,965
Notes payable- related party	333,333
Total Liabilities	3,332,683	1,995,991
Stockholders’ Equity
Series A preferred stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding, as of September 30, 2022 and December 31, 2021.
Common stock, $0.00001 par value; 100,000,000 shares authorized; 8,398,708 and 8,166,457 shares issued and outstanding, as of September 30, 2022 and December 31, 2021, respectively	83	82
Additional paid-in capital	20,193,271	20,017,528
Retained deficit	(18,794,350)	(16,247,437)
Total	1,399,004	3,770,173
Non-controlling interest in subsidiary	(42,426)
Total stockholders’ equity	1,356,578	3,770,173
Total Liabilities and Stockholders’ Equity	$ 4,689,261	$ 5,766,164

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	8,398,708	8,166,457
Common stock, shares outstanding	8,398,708	8,166,457

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 2,400,311	$ 2,550,046	$ 8,919,312	$ 7,501,535
Cost of Sales	998,320	1,269,005	5,010,704	3,995,792
Gross Profit	1,401,991	1,281,041	3,908,608	3,505,743
Operating Expenses:
Loss on inventory investment		1,285		1,226,426
Wage and salary expense	937,062	1,015,816	3,185,144	2,878,237
Professional fees	95,275	205,457	307,341	757,263
Accounting and legal expense	191,611	98,867	567,690	462,626
Technology expense	298,586	338,637	842,433	678,110
General and administrative	286,488	917,105	1,484,709	2,013,050
Total operating expenses	1,809,022	2,577,167	6,387,317	8,015,712
Operating Loss	(407,031)	(1,296,126)	(2,478,709)	(4,509,969)
Nonoperating income (expense)
Interest income	8,396		8,396
Gain on disposal of asset			4,100
Interest expense	(130,107)	(5,622)	(140,626)	(21,574)
Total nonoperating expense	(121,711)	(5,622)	(128,130)	(21,574)
Net Loss	(528,742)	(1,301,748)	(2,606,839)	(4,531,543)
Net loss attributable to TRxADE Health, Inc.	(503,003)	(1,301,748)	(2,546,913)	(4,531,543)
Net loss attributable to non-controlling interests	$ (25,739)		$ (59,926)
Net loss per common share — basic and diluted	$ (0.06)	$ (0.16)	$ (0.31)	$ (0.56)
Weighted average common shares outstanding - basic and diluted	8,249,653	8,163,522	8,203,202	8,126,689

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 81	$ 19,610,631	$ (10,931,554)		$ 8,679,158
Balance, shares at Dec. 31, 2020		8,093,199
Common Stock Issued for Services, shares
Common stock issued for services			98,247			98,247
Options expense			75,738			75,738
Net loss				(651,519)		(651,519)
Ending balance, value at Mar. 31, 2021		$ 81	19,784,616	(11,583,073)		8,201,624
Balance, shares at Mar. 31, 2021		8,093,199
Beginning balance, value at Dec. 31, 2020		$ 81	19,610,631	(10,931,554)		8,679,158
Balance, shares at Dec. 31, 2020		8,093,199
Net loss						(4,531,543)
Ending balance, value at Sep. 30, 2021		$ 82	20,080,310	(15,463,097)		4,617,295
Balance, shares at Sep. 30, 2021		8,166,457
Beginning balance, value at Mar. 31, 2021		$ 81	19,784,616	(11,583,073)		8,201,624
Balance, shares at Mar. 31, 2021		8,093,199
Common stock issued for services			100,416			100,416
Options expense			61,392			61,392
Net loss				(2,578,276)		(2,578,276)
Options exercised for cash			1,821			1,821
Ending balance, value at Jun. 30, 2021		$ 81	19,948,245	(14,161,349)		5,786,977
Balance, shares at Jun. 30, 2021		8,161,457
Common stock issued for services			41,250			41,250
Warrants exercised for cash		1	15,000			15,001
Options expense			54,175			54,175
Net loss				(1,301,748)		(1,301,748)
Warrants expense			21,640			21,640
Ending balance, value at Sep. 30, 2021		$ 82	20,080,310	(15,463,097)		4,617,295
Balance, shares at Sep. 30, 2021		8,166,457
Beginning balance, value at Dec. 31, 2021		$ 82	20,017,528	(16,247,437)		3,770,173
Balance, shares at Dec. 31, 2021		8,166,457
Capital Contributions					792,500	792,500
Capital distributions					(775,000)	(775,000)
Common stock issued for services			32,083			32,083
Warrants exercised for cash			875			875
Warrants Exercised for Cash, shares		14,584
Options expense			32,783			32,783
Net loss				(960,147)	(5,689)	(965,836)
Ending balance, value at Mar. 31, 2022		$ 82	20,083,269	(17,207,584)	11,811	2,887,578
Balance, shares at Mar. 31, 2022		8,181,041
Beginning balance, value at Dec. 31, 2021		$ 82	20,017,528	(16,247,437)		3,770,173
Balance, shares at Dec. 31, 2021		8,166,457
Net loss						(2,606,839)
Ending balance, value at Sep. 30, 2022		$ 83	20,193,271	(18,794,350)	(42,426)	1,356,578
Balance, shares at Sep. 30, 2022		8,398,708
Beginning balance, value at Mar. 31, 2022		$ 82	20,083,269	(17,207,584)	11,811	2,887,578
Balance, shares at Mar. 31, 2022		8,181,041
Capital Contributions
Common Stock Issued for Services, shares		37,905
Common stock issued for services			12,222			12,222
Warrants exercised for cash
Options expense			16,994			16,994
Net loss				(1,083,763)	(28,498)	(1,112,261)
Options exercised for cash, shares		30,353
Ending balance, value at Jun. 30, 2022		$ 82	20,112,485	(18,291,347)	(16,687)	1,804,533
Balance, shares at Jun. 30, 2022		8,181,041
Capital Contributions
Common Stock Issued for Services, shares		217,667
Common stock issued for services		$ 1	63,125			63,126
Warrants exercised for cash
Warrants Exercised for Cash, shares		5,000
Options expense			17,661			17,661
Net loss				(503,003)	(25,739)	(528,742)
Ending balance, value at Sep. 30, 2022		$ 83	$ 20,193,271	$ (18,794,350)	$ (42,426)	$ 1,356,578
Balance, shares at Sep. 30, 2022		8,398,708

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (2,606,839)	$ (4,531,543)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	11,815	5,250
Options expense	67,439	191,305
Common stock issued for services	107,430	239,913
Bad debt expense	(98,841)	616,215
Warrant Expense		21,640
Loss on inventory investments		1,226,426
Gain on sale of asset	(4,100)
Amortization of right of use assets	132,847	97,436
Amortization of intangible assets	29,400
Changes in operating assets and liabilities:
Deferred offering costs		(78,000)
Accounts receivable, net	227,508	(819,988)
Prepaid assets and deposits	198,088	(284,499)
Inventory	(19,671)	1,162,932
Other receivables	(875,250)	5,140
Lease liability	(120,401)	(96,954)
Accounts payable	267,384	18,391
Accrued liabilities	(178,714)	96,825
Current liabilities	105,926
Customer Deposits		(10,000)
Net cash used in operating activities	(2,755,979)	(2,139,511)
Cash flows from investing activities:
Sale of fixed assets	23,000
Investment in capitalized software	(335,902)
Net cash used in investing activities	(312,902)
Cash flows from financing activities:
Repayments of promissory notes- related parties		(225,000)
Repayment of contingent liability	(282,857)
Distributions to non-controlling interest	(275,000)
Proceeds from sale of future revenue	825,000
Proceeds from exercise of stock options		1,821
Proceeds from exercise of warrants	875	15,001
Net cash provided by financing activities	268,018	(208,178)
Net decrease in cash	(2,800,863)	(2,347,689)
Cash at beginning of the year	3,122,578	5,919,578
Cash at end of the period	321,715	3,571,889
Supplemental disclosure of cash flow information
Cash paid for interest	3,328	26,321
Cash Paid for income taxes
Non-Cash Transactions
Insurance premium financed	220,354
Note issued as SOSRx contribution	500,000
Intangible asset contribution from non-controlling interest	$ 792,500

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION TRxADE HEALTH, INC. (“ we our Trxade Company 100 100 Trxade, Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC (d.b.a. Trxade Prime), is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. Trxade Prime customers include all healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Alliance Pharma Solutions, LLC (d.b.a. DelivMeds) invested in SyncHealth MSO, LLC, a managed services organization, in January 2019, which investment was divested in February 2020. DelivMeds is currently being rebranded and the consumer-based app is still being developed. To date, we have not generated any revenue from this product. Community Specialty Pharmacy, LLC, is an accredited independent retail pharmacy with a focus on a community-based model offering home delivery services to patients. Bonum Health, LLC, was formed to hold certain telehealth assets acquired in October 2019. The “ Bonum Health Hub 143,891 On February 15, 2022, the Company entered into a relationship with Exchange Health, LLC, a technology company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals (“Exchange Health”). SOSRx LLC, the created entity relating to the relationship, a Delaware limited liability company, was formed in February 2022, and is owned 51 49 Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2021, as reported in the Company’s Annual Report on Form 10-K have been omitted. Accounts Receivable – 98,841 616,215 The Company had an Account Receivable with a single customer, GSG PPE, LLC (“GSG”), for the amount of $ 630,000 Other Receivables CSP 1,200,000 875,000 875,000 Income (loss) Per Common Share 26,924 338,857 The following table sets forth the computation of basic and diluted loss per share: SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss $ (528,742 ) $ (1,301,748 ) $ (2,606,839 ) $ (4,531,543 ) Numerator for basic and diluted EPS - income available to common stockholders (503,003 ) (1,301,748 ) (2,546,913 ) (4,531,543 ) Denominator: Denominator for basic and diluted EPS – weighted average shares 8,249,653 8,163,522 8,203,202 8,126,689 Basic and diluted loss per common share $ (0.06 ) $ (0.16 ) $ (0.31 ) $ (0.56 )

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of September 30, 2022 the Company had an accumulated deficit of $ 18.8 0.3 0.3

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 3– RELATED PARTY TRANSACTIONS On February 15, 2022, the Company entered into a relationship with Exchange Health, a technology company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals. In connection therewith, SOSRx LLC (“SOSRx”), was formed in February 2022, which is owned 51 49 325,000 500,000 400,000 792,000 15 29,400 At September 30, 2022, total related party debt was $ 500,000 0 2 8.25 166,666.67 41,666.67

CONTINGENT FUNDING LIABILITIES

CONTINGENT FUNDING LIABILITIES	9 Months Ended
	Sep. 30, 2022
Contingent Funding Liabilities
CONTINGENT FUNDING LIABILITIES	NOTE 4 – CONTINGENT FUNDING LIABILITIES On September 14, 2022, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $ 275,000 396,000 15,000 On June 27, 2022, the Company entered into a non-recourse funding agreement with a third-party funder for the purchase and sale of future receivables. Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $ 550,000 792,000 27,500 The Company’s relationship with the funding source meets the criteria in ASC 470-10-25 – Sales of Future Revenues or Various Other Measures of Income (“ASC 470”), which relates to cash received from a funding source in exchange for a specified percentage or amount of revenue or other measure of income of a particular product line, business segment, trademark, patent or contractual right for a defined period. Under this guidance, the Company recognized the fair value of its contingent obligation to the funding source, as of the acquisition date, as a current liability in its consolidated balance sheet. Under ASC 470, amounts recorded as debt are to be amortized under the interest method. The Company made an accounting policy election to utilize the prospective method when there is a change in the estimated future cash flows, whereby a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining period. Under this method, the effective interest rate is not constant, and any change in expected cash flows is recognized prospectively as an adjustment to the effective yield. As of September 30, 2022 the total contingent funding liability was $ 542,143 36

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 5 – STOCKHOLDERS’ EQUITY 2022 Equity Compensation Awards Effective September 1, 2022, the Board of Directors and Compensation Committee of the Company, with the approval of each of the following officers, agreed to reduce the annual cash compensation payable to Suren Ajjarapu, the Company’s Chief Executive Officer; Prashant Patel, the Company’s President and Chief Operating Officer and Janet Huffman, the Company’s Chief Financial Officer, in an effort to conserve cash. In lieu of the reduced cash salary payable to each officer, the Board and Compensation Committee agreed to issue such officers shares of the Company’s common stock equal to the amount of reduced cash salary, divided by the closing sales price of the Company’s common stock on the NASDAQ Capital Market on August 31, 2022, the date approved by the Board of Directors. The total amount of shares of common stock issued on August 31, 2022 to the officers was 81,895 The shares of common stock issuable to the officers vest at the rate of 1/4th of such shares on each of September 30, 2022, October 31, 2022, November 30, 2022, and December 31, 2022, subject to each applicable Officer’s continued service to the Company on such dates and subject to the restricted stock award agreements entered into to evidence such awards. Separately, certain employees of the Company agreed to reduce their cash salaries by an aggregate of $ 37,000 31,896 Effective on August 31, 2022, the Board of Directors approved the issuance of 54,525 63,250 All of the awards discussed above were issued under the Company’s Second Amended and Restated 2019 Equity Incentive Plan (the “Plan”) and all restricted stock awards discussed above were evidenced by Restricted Stock Grant Agreements. 2021 Equity Compensation Awards On April 15, 2021, the Board of Directors, with the recommendation of the Compensation Committee, approved the grant of options to purchase an aggregate of 17,500 th five years 4.76 In connection with and pursuant to the independent director compensation policy previously adopted by the Board of Directors, on April 15, 2021, the then three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were each awarded 10,721 55,000 5.13 th 165,000 41,250 16,082 The Board of Directors of the Company, on May 27, 2021, confirmed the vesting of 2,680 In connection with and pursuant to the independent director compensation policy previously adopted by the Board of Directors, on May 27, 2021, the Board of Directors awarded Charles L. Pope, and Christine L. Jennings, each independent members of the Board of Directors appointed to the Board of Directors on May 27, 2021, 10,912 41,250 3.78 174,869 431,218 Employment Agreement with Suren Ajjarapu, Chief Executive Officer In connection with our employment agreement with Mr. Suren Ajjarapu, our Chief Executive Officer, which was effective on April 14, 2020, we granted 49,020 300,000 72,062 49,020 no Stock Repurchase Program On May 27, 2021, the Board of Directors of the Company authorized and approved a share repurchase program for up to $ 1 There was no time frame or expiration date for the repurchase program, and such program was to remain in place until a maximum of $1.0 million of the Company’s common stock had been repurchased or until such program was suspended or discontinued by the Board of Directors On July 18, 2021, our Board of Directors approved an “at-the-market” offering and paused the Stock Repurchase Program until the offering was complete. On July 22, 2021, our Board of Directors delayed the “at-the-market” offering and reactivated the Stock Repurchase Program. On August 5, 2021, our Board of Directors paused the Stock Repurchase Program until a planned “at-the-market” offering was complete, which “at-the-market” offering was terminated effective on December 5, 2021. On December 10, 2021, the Board of Directors authorized and approved the resumption of the Company’s prior share repurchase program (as modified), as discussed above. The share repurchase program as approved by the Board of Directors on December 10, 2021, modified the prior repurchase program to allow for the repurchase of up to 100,000 There is no time frame for the repurchase program, and such program will remain in place until a maximum of 100,000 shares of the Company’s common stock have been repurchased or until such program is discontinued by the Board of Directors To date, no shares of common stock have been repurchased by the Company.

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2022
Warrants
WARRANTS	NOTE 6 – WARRANTS For the nine-month period ended September 30, 2022, no 3,027 14,584 875 14,584 The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant. There was no The Company’s outstanding and exercisable warrants as of September 30, 2022, are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Price Contractual Life In Years Warrants outstanding as of December 31, 2021 44,535 $ 0.32 0.95 $ 208,078 Warrants granted - - - - Warrants forfeited, expired, cancelled (3,027 ) 3.90 - - Warrants exercised (14,584 ) 0.06 - - Warrants outstanding as of September 30, 2022 26,924 $ 0.06 0.75 $ 28,809 Warrants exercisable as of September 30, 2022 26,924 $ 0.06 0.75 $ 28,809

OPTIONS

OPTIONS	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
OPTIONS	NOTE 7 – OPTIONS The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 2,333,333 2,000,000 st beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator. The administrator did not approve an increase in the number of shares covered under the plan as of April 1, 2022 or 2021 For the nine-month period ended September 30, 2022, no 10,207 61,900 no Total compensation cost related to stock options granted was $ 67,439 137,130 The following table represents stock option activity for the nine-month period ended September 30, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted Average Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2021 410,964 $ 4.78 4.67 $ 368,417 Options Exercisable as of December 31, 2021 302,191 $ 4.88 4.38 $ 257,186 Options granted - $ - - $ - Options forfeited (10,207 ) $ 4.73 3.91 $ - Options expired (61,900 ) $ 5.56 2.05 $ - Options exercised - $ - - $ - Options outstanding as of September 30, 2022 338,857 $ 4.64 4.26 $ - Options exercisable as of September 30, 2022 286,841 $ 4.64 4.15 $ -

CONTINGENCIES

CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	NOTE 8 – CONTINGENCIES Studebaker Defense Group, LLC In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $ 500,000 180,000 500,000 500,000 Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $ 581,250 150,000 581,250 581,250 581,250 GSG PPE, LLC On November 19, 2021, Integra filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and Integra executed a valid initial contract setting the terms of a business transaction. GSG failed to pay Integra approximately 75% of the amount owed to Integra. GSG acknowledged it owed the money and executed a promissory note in favor of Integra in the amount of $ 630,000 630,000 630,000 630,000 743,000 100,000 Jain, et al., v. Memantine, et al. In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. On May 14, 2021, Plaintiffs filed a second amended complaint against the defendants. The second amended complaint alleges causes of action against the defendants including securities fraud, breach of fiduciary duty, violation of the Florida RICO Act, and breach of contract. The operative complaint relates to certain investments alleged to have been made by the plaintiffs in Nexgen Memantine and certain alleged transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The amended complaint seeks injunctive relief, $ 425,000 In February 2022, a settlement as to Suren Ajjarapu, Annapurna Gundlapalli and the Company was reached and signed. This settlement involved no admission of liability and a full and complete release of all actions after a lump-sum payment of $ 225,000

LEASES

LEASES	9 Months Ended
	Sep. 30, 2022
Leases
LEASES	NOTE 9 – LEASES The Company elected the practical expedient under Accounting Standards Update (ASU) 2018-11 “Leases: Targeted Improvements” which allows the Company to apply the transition provision for Topic 842 at the Company’s adoption date instead of at the earliest comparative period presented in the financial statements. Therefore, the Company recognized and measured leases existing at January 1, 2019, but without retrospective application. In addition, the Company elected the optional practical expedient permitted under the transition guidance which allows the Company to carry forward the historical accounting treatment for existing leases upon adoption. No impact was recorded to the beginning retained earnings for Topic 842. The Company has two operating leases for corporate offices. The following table outlines the details: SCHEDULE OF OPERATING LEASES Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of right-of-use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 % The Company entered into a new corporate office lease (Lease 1) on January 1, 2022. The Company determined that entering into a new lease required remeasurement of the lease liability resulting in the increase of the right-of-use asset and the associated lease liability by $ 977,220 15,000 The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of September 30, 2022. SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES Amounts due within twelve months of September 30, 2022 2022 $ 291,537 2023 300,286 2024 309,294 2025 318,573 2026 122,912 Thereafter 63,055 Total minimum lease payments 1,405,657 Less: effect of discounting (291,713 ) Present value of future minimum lease payments 1,113,944 Less: current obligations under leases 188,558 Long-term lease obligations $ 925,386 The difference to the balance sheet above is due to the current and long-term remaining lease obligations of the copier operating lease not included in the amount of $ 14,181 For the nine-months ended September 30, 2022, and 2021, amortization of Right of Use Assets was $ 132,847 97,436 120,403 and $ 96,954

SEGMENT REPORTING

SEGMENT REPORTING	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 10 – SEGMENT REPORTING Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. The Company classifies its business interests into reportable segments which are: ● Trxade, Inc. - Web based pharmaceutical marketplace platform – B2B sales ● CSP - Community Specialty Pharmacy, LLC – Licensed retail pharmacy – B2C sales ● Integra - Integra Pharma, LLC - Licensed wholesaler of brand, generic and non-drug products – B2B sales ● Unallocated - Other – corporate overhead expense, Alliance Pharma Solutions, LLC and Bonum Health, LLC SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Nine Months Ended September 30, 2022 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 4,001,670 $ 905,083 $ 3,949,772 $ 62,787 $ 8,919,312 Gross Profit 4,001,670 (114,387 ) (41,462 ) 62,787 3,908,608 Segment Assets 1,853,474 236,827 454,783 2,111,177 4,689,261 Segment Profit (Loss ) 1,320,138 (363,212 ) (493,203 ) (3,070,562 ) (2,606,839 ) Cost of Sales $ - $ 1,019,470 $ 3,991,234 $ - $ 5,010,704 Nine Months Ended September 30, 2021 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 3,653,269 $ 1,287,296 $ 2,511,270 $ 49,700 $ 7,501,535 Gross Profit 3,652,015 123,470 (319,104 ) 49,362 3,505,743 Segment Assets 1,487,657 (404,174 ) 563,396 3,867,221 5,514,101 Segment Profit (Loss) 1,511,809 (89,025 ) (2,500,032 ) (3,454,295 ) (4,531,543 ) Cost of Sales $ 1,254 $ 1,163,826 $ 2,830,374 $ 338 $ 3,995,792

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS Appointment of Directors On September 30, 2022, Mr. Jeff Newell was appointed to the Board of Directors. Securities Purchase Agreement On October 4, 2022 the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”). The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of: (i) 920,000 0.00001 601,740 2,663,045 1.15 1.14999 The Pre-Funded Warrants have cashless exercise rights and to the extent the shares of common stock underlying the Private Placement Warrants are not registered under the Securities Act, the Private Placement Warrants include cashless exercise rights. Under the terms of the Pre-Funded Warrants and Private Placement Warrants, a holder will not be entitled to exercise any portion of any such warrant, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder’s affiliates, and any other persons whose beneficial ownership of Common Stock would or could be aggregated with the holder’s for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) would exceed 4.99 the Company subject to the terms of such warrants, provided that such percentage may in no event exceed 9.99%, and provided further that the Purchaser has elected to increase the ownership limitation to 9.99% in connection with the initial issuance of the Pre-Funded Warrants The Private Placement Warrants may not be exercised by the holder thereof until or unless the Company’s stockholders have approved the issuance of shares of Common Stock upon the exercise of such Private Placement Warrants pursuant to the applicable rules and regulations of the Nasdaq Stock Market, including the issuance of the shares of Common Stock issuable upon exercise of the Private Placement Warrants in excess of 19.99 Stockholder Approval As an additional requirement to the offering, all of the officers and directors of the Company were required to enter into an agreement agreeing to vote all Common Stock over which such persons have voting control as of the record date for the meeting of stockholders of the Company (the “ Voting Agreement The offering of the Shares, Pre-Funded Warrants and Private Placement Warrants resulted in gross proceeds to the Company of approximately $ 1.75 1.5 Additionally, each of the directors and executive officers of the Company, pursuant to lock-up agreements (the “ Lock-Up Agreements We agreed pursuant to the Purchase Agreement that as soon as practicable (and in any event within 60 calendar days of the date of Purchase Agreement), that we would file a registration statement on Form S-1 providing for the resale by the Purchaser of the shares of Common Stock issuable upon exercise of the Private Placement Warrants, use commercially reasonable efforts to cause such registration statement to become effective within 181 days following the closing date of the offerings and to keep such registration statement effective at all times until no Purchaser owns any Private Placement Warrants or shares of Common Stock issuable upon exercise thereof. The date such required registration statement is declared effective is defined herein as the “ Effective Date We also agreed to hold a special meeting of stockholders (which may also be at the annual meeting of stockholders) or take action via written consent of stockholders, at the earliest practical date, but no later than December 20, 2022, for the purpose of obtaining Shareholder Approval, with the recommendation of the Company’s Board of Directors that such proposal be approved, and to solicit proxies from our stockholders in connection therewith. We are required to use our reasonable best efforts to obtain such Shareholder Approval. If we do not obtain Shareholder Approval at the first meeting, we are required to call a meeting every six months thereafter to seek Shareholder Approval until the earlier of the date Shareholder Approval is obtained or the Private Placement Warrants are no longer outstanding. Pursuant to the Purchase Agreement the Company has agreed that, subject to certain exceptions, (i) it will not issue any shares of Common Stock for a period of 90 days following the later of (A) the date of Stockholder Approval and (B) the Effective Date, subject to certain customary and pre-agreed exceptions and that (ii) it will not enter into a variable rate transaction for a period of nine months following the Effective Date. We also agreed to provide the Purchaser a right of participation for 12 months following the closing date to participate up to 25% in any subsequent offering we may undertake of equity or debt. The transactions contemplated by the Purchase Agreement closed on October 7, 2022. On October 4, 2022, the Company also entered into a placement agent agreement (the “ Placement Agent Agreement Placement Agent 7.0 35,000 Nasdaq Shareholder Equity Listing Requirements On July 29, 2022, the Company received a letter from The Nasdaq Stock Market LLC (“ Nasdaq Rule 2,500,000 1,804,533

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE	The following table sets forth the computation of basic and diluted loss per share: SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss $ (528,742 ) $ (1,301,748 ) $ (2,606,839 ) $ (4,531,543 ) Numerator for basic and diluted EPS - income available to common stockholders (503,003 ) (1,301,748 ) (2,546,913 ) (4,531,543 ) Denominator: Denominator for basic and diluted EPS – weighted average shares 8,249,653 8,163,522 8,203,202 8,126,689 Basic and diluted loss per common share $ (0.06 ) $ (0.16 ) $ (0.31 ) $ (0.56 )

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS	The Company’s outstanding and exercisable warrants as of September 30, 2022, are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Price Contractual Life In Years Warrants outstanding as of December 31, 2021 44,535 $ 0.32 0.95 $ 208,078 Warrants granted - - - - Warrants forfeited, expired, cancelled (3,027 ) 3.90 - - Warrants exercised (14,584 ) 0.06 - - Warrants outstanding as of September 30, 2022 26,924 $ 0.06 0.75 $ 28,809 Warrants exercisable as of September 30, 2022 26,924 $ 0.06 0.75 $ 28,809

OPTIONS (Tables)

OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table represents stock option activity for the nine-month period ended September 30, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted Average Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2021 410,964 $ 4.78 4.67 $ 368,417 Options Exercisable as of December 31, 2021 302,191 $ 4.88 4.38 $ 257,186 Options granted - $ - - $ - Options forfeited (10,207 ) $ 4.73 3.91 $ - Options expired (61,900 ) $ 5.56 2.05 $ - Options exercised - $ - - $ - Options outstanding as of September 30, 2022 338,857 $ 4.64 4.26 $ - Options exercisable as of September 30, 2022 286,841 $ 4.64 4.15 $ -

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
SCHEDULE OF OPERATING LEASES	SCHEDULE OF OPERATING LEASES Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of right-of-use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 %
SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES	SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES Amounts due within twelve months of September 30, 2022 2022 $ 291,537 2023 300,286 2024 309,294 2025 318,573 2026 122,912 Thereafter 63,055 Total minimum lease payments 1,405,657 Less: effect of discounting (291,713 ) Present value of future minimum lease payments 1,113,944 Less: current obligations under leases 188,558 Long-term lease obligations $ 925,386

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS	SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Nine Months Ended September 30, 2022 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 4,001,670 $ 905,083 $ 3,949,772 $ 62,787 $ 8,919,312 Gross Profit 4,001,670 (114,387 ) (41,462 ) 62,787 3,908,608 Segment Assets 1,853,474 236,827 454,783 2,111,177 4,689,261 Segment Profit (Loss ) 1,320,138 (363,212 ) (493,203 ) (3,070,562 ) (2,606,839 ) Cost of Sales $ - $ 1,019,470 $ 3,991,234 $ - $ 5,010,704 Nine Months Ended September 30, 2021 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 3,653,269 $ 1,287,296 $ 2,511,270 $ 49,700 $ 7,501,535 Gross Profit 3,652,015 123,470 (319,104 ) 49,362 3,505,743 Segment Assets 1,487,657 (404,174 ) 563,396 3,867,221 5,514,101 Segment Profit (Loss) 1,511,809 (89,025 ) (2,500,032 ) (3,454,295 ) (4,531,543 ) Cost of Sales $ 1,254 $ 1,163,826 $ 2,830,374 $ 338 $ 3,995,792

SCHEDULE OF BASIC AND DILUTIVE

SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Net loss	$ (528,742)	$ (1,112,261)	$ (965,836)	$ (1,301,748)	$ (2,578,276)	$ (651,519)	$ (2,606,839)	$ (4,531,543)
Numerator for basic and diluted EPS - income available to common stockholders	$ (503,003)			$ (1,301,748)			$ (2,546,913)	$ (4,531,543)
Denominator for basic and diluted EPS – weighted average shares	8,249,653			8,163,522			8,203,202	8,126,689
Basic and diluted loss per common share	$ (0.06)			$ (0.16)			$ (0.31)	$ (0.56)

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	May 23, 2022	May 20, 2022	Feb. 15, 2022	Dec. 31, 2021
Bad debt expense	$ 98,841	$ 616,215
Accounts receivable, after allowance for credit loss, current	850,306					$ 978,973
Warrants to purchase common stock	$ 26,924
Number of options outstanding	338,857
Single Customer [Member]
Accounts receivable, after allowance for credit loss, current	$ 630,000
Bonum Health Hub [Member]
Loss on inventory investments	$ 143,891
Community Specialty Pharmacy, LLC [Member]
Other receivables				$ 1,200,000
Payment of other receivables			$ 875,000
Trxade, Inc.[Member]
Equity method investment, ownership percentage	100%
MedChecks, LLC [Member]
Equity method investment, ownership percentage	100%
SosRx LLC [Member]
Equity method investment, ownership percentage					51%
Exchange Health LLC [Member]
Equity method investment, ownership percentage					49%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 18,794,350	$ 16,247,437
Working capital	300,000
Cash balance	$ 321,715	$ 3,122,578

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		9 Months Ended
	Feb. 15, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Promissory note issued		$ 500,000
Finite lived intangible asset useful life	15 years
Amortization of intangible assets		29,400
Related party debt		$ 500,000		$ 0
Debt instrument principal amount			$ 630,000
Exchange Health LLC [Member]
Interest basis spread	2%
Interest rate	8.25%
Debt instrument principal amount	$ 166,666.67
Debt instrument installment amount	41,666.67
Exchange Health LLC [Member] | Software and contracts [Member]
Proceeds from intangible assets.	792,000
SosRx LLC [Member]
Related party transaction amount	325,000
Promissory note issued	500,000
Other commitment	$ 400,000
SosRx LLC [Member]
Equity method investment, ownership percentage	51%
Exchange Health LLC [Member]
Equity method investment, ownership percentage	49%

CONTINGENT FUNDING LIABILITIES

CONTINGENT FUNDING LIABILITIES (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 14, 2022	Jun. 27, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent funding liability	$ 542,143
Receivables agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent funding liability	$ 542,143	$ 275,000	$ 550,000
Receivables net current		396,000	792,000
One-time origination fee		$ 15,000	$ 27,500
Interest rate	36%

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Aug. 31, 2022

Dec. 10, 2021

May 27, 2021

Apr. 15, 2021

Apr. 14, 2020

Sep. 30, 2022

Sep. 30, 2022

Jun. 30, 2022

Mar. 31, 2022

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Jun. 30, 2022

Jun. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Dec. 31, 2021

Dec. 31, 2020

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during period value issued for services

$ 63,126

$ 12,222

$ 32,083

$ 41,250

$ 100,416

$ 98,247

Share based compensation

$ 67,439

$ 137,130

Restricted Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based compensation

$ 37,000

Share based compensation

31,896

Officers [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Common stock shares issued

81,895

Board of Directors Chairman [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during period shares issued for services

54,525

Stock issued during period value issued for services

$ 63,250

Board of Directors [Member] | Stock Repurchase Program [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock repurchase program description

There is no time frame for the repurchase program, and such program will remain in place until a maximum of 100,000 shares of the Company’s common stock have been repurchased or until such program is discontinued by the Board of Directors

There was no time frame or expiration date for the repurchase program, and such program was to remain in place until a maximum of $1.0 million of the Company’s common stock had been repurchased or until such program was suspended or discontinued by the Board of Directors

Board of Directors [Member] | Stock Repurchase Program [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares repurchase value approved

$ 1,000,000

Shares repurchased

100,000

Board of Directors [Member] | 2021 Equity Compensation Awards [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options to purchase shares of common stock

17,500

Options term

5 years

Exercise price per share

$ 4.76

Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson [Member] | 2021 Equity Compensation Awards [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of restricted stock

10,721

Shares of restricted stock, value

$ 55,000

$ 165,000

Price per share

$ 5.13

Share based compensation

$ 41,250

$ 41,250

Mr. Peterson and Ms. Tenaerts [Member] | 2021 Equity Compensation Awards [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock redeemed or called during period, shares

16,082

Michael L. Peterson and Dr. Pamela Tenaert [Member] | 2021 Equity Compensation Awards [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of common stock vested

2,680

Charles L. Pope, and Christine L. Jennings [Member] | 2021 Equity Compensation Awards [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of restricted stock

10,912

Shares of restricted stock, value

$ 41,250

Price per share

$ 3.78

Share based compensation

$ 174,869

$ 431,218

Suren Ajjarapu [Member] | Employment Agreement [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of restricted stock

49,020

Shares of restricted stock, value

$ 300,000

Shares of common stock vested

0

49,020

Incremental value

$ 72,062

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Warrants
Number of Outstanding Shares, Warrants Outstanding Beginning | shares	44,535
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 0.32
Contractual Life in Years Warrants Outstanding, Beginning	11 months 12 days
Aggregate Intrinsic Value Outstanding Beginning | $	$ 208,078
Number of Outstanding Shares, Warrants Granted | shares
Weighted Average Exercise Price, Warrants Granted | $ / shares
Number of Outstanding Shares, Warrants forfeited, expired, cancelled | shares	(3,027)
Weighted Average Exercise Price, Warrants forfeited, expired, cancelled | $ / shares	$ 3.90
Number of Outstanding Shares, Warrants Exercised | shares	(14,584)
Weighted Average Exercise Price, Warrants Exercised | $ / shares	$ 0.06
Number of Outstanding Shares, Warrants Outstanding Ending | shares	26,924
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 0.06
Contractual Life in Years Warrants, Warrants Exercisable Ending	9 months
Aggregate Intrinsic Value Outstanding Ending | $	$ 28,809
Number of Outstanding Shares, Warrants Exercisable Ending | shares	26,924
Weighted Average Exercise Price, Warrants Exercisable Ending | $ / shares	$ 0.06
Aggregate Intrinsic Value Warrants Exercisable Ending | $	$ 28,809

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Number of warrants granted
Warrants exercised	14,584
Proceeds from warrant exercises	$ 875	$ 15,001
Share-based payment arrangement, noncash expense	$ 67,439	137,130
Warrant [Member]
Number of warrants granted	0
Warrants, expired	3,027
Warrants exercised	14,584
Proceeds from warrant exercises	$ 875
Number of warrants delivered	14,584
Share-based payment arrangement, noncash expense	$ 0	$ 0

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - Stock Options [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning Balance	410,964
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 4.78
Contractual Life in Years Outstanding, Ending Balance	4 years 3 months 3 days	4 years 8 months 1 day
Intrinsic Value Outstanding, Beginning Balance	$ 368,417
Number of Outstanding, Options Exercisable, Beginning Balance	302,191
Weighted Average Exercise Price Exercisable, Beginning Balance	$ 4.88
Contractual Life in Years Exercisable, Ending Balance	4 years 1 month 24 days	4 years 4 months 17 days
Intrinsic Value Exercisable, Beginning Balance	$ 257,186
Number of Outstanding, Options Grants
Weighted Average Exercise Price, Grants
Number of Outstanding ,Options Forfeited	(10,207)
Weighted Average Exercise Price, Forfeited	$ 4.73
Contractual Life in Years, Forfeited	3 years 10 months 28 days
Number of Outstanding, Option Expired	(61,900)
Weighted Average Exercise Price, Expired	$ 5.56
Contractual Life in Years, Expired	2 years 18 days
Number of Outstanding, Options Exercised
Weighted Average Exercise Price, Exercised
Number of Options Outstanding, Ending Balance	338,857	410,964
Weighted Average Exercise Price Outstanding, Ending Balance	$ 4.64	$ 4.78
Intrinsic Value Outstanding, Ending Balance		$ 368,417
Number of Options Exercisable, Ending Balance	286,841	302,191
Weighted Average Exercise Price Exercisable, Ending Balance	$ 4.64	$ 4.88
Intrinsic Value Exercisable, Ending Balance		$ 257,186

OPTIONS (Details Narrative)

OPTIONS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options expense	$ 67,439	$ 137,130
Share-Based Payment Arrangement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options to purchase common stock granted	0
Options to purchase common stock forfeited	10,207
Options to purchase common stock expired	61,900
Number of options, exercised	0
Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options to purchase common stock granted	2,333,333
Second Amended and Restated 2019 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued during period, shares	2,000,000
Share-based payment award, description	beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator. The administrator did not approve an increase in the number of shares covered under the plan as of April 1, 2022 or 2021

CONTINGENCIES (Details Narrativ

CONTINGENCIES (Details Narrative)			1 Months Ended			3 Months Ended		6 Months Ended	9 Months Ended
	May 14, 2021 USD ($)	Aug. 14, 2020 Integer	Feb. 28, 2022 USD ($)	Aug. 31, 2020 USD ($) Integer	Jul. 31, 2020 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Loss on inventory investment							$ 1,285			$ 1,226,426
Debt instrument face amount							$ 630,000			630,000
Attorney fees									630,000
Bad debt expense										$ 630,000
Compensatory amount value	$ 425,000
Settlement payment amount			$ 225,000
Waxman [Member]
Debt instrument face amount						$ 630,000			630,000
Attorney fees								$ 743,000
Integra [Member] | Studebaker Defense Group, LLC [Member]
Down payment					$ 500,000
Number of nitrile gloves delivered | Integer		180,000
Loss contingency, damages sought, value					$ 500,000
Loss on inventory investment								$ 500,000
Integra [Member] | Sandwave Group Dsn Bhd [Member]
Down payment				$ 581,250
Number of nitrile gloves delivered | Integer				150,000
Loss contingency, damages sought, value				$ 581,250
Loss on inventory investment									581,250
Integra [Member] | Crecom Burj Group Sdn Bhd [Member]
Loss contingency, damages sought, value				$ 581,250
GSG PPE LLC [Member]
Payment received									$ 100,000

SCHEDULE OF OPERATING LEASES (D

SCHEDULE OF OPERATING LEASES (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Jan. 01, 2019
Property, Plant and Equipment [Line Items]
Recognition of Right to use assets	$ 1,100,186	$ 1,233,033
Lease 1 [Member]
Property, Plant and Equipment [Line Items]
Initial Lease Term	December 2017 to December 2021
Renewal Term	January 2021 to December 2024
Recognition of Right to use assets			$ 534,140
Incremental Borrowing Rate	10%
Lease 2 [Member]
Property, Plant and Equipment [Line Items]
Initial Lease Term	November 2018 to November 2023
Renewal Term	November 2023 to November 2028
Recognition of Right to use assets			$ 313,301
Incremental Borrowing Rate	10%

SCHEDULE OF FUTURE MINIMUM PAYM

SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES (Details)	Sep. 30, 2022 USD ($)
Leases
2022	$ 291,537
2023	300,286
2024	309,294
2025	318,573
2026	122,912
Thereafter	63,055
Total minimum lease payments	1,405,657
Less: effect of discounting	(291,713)
Present value of future minimum lease payments	1,113,944
Less: current obligations under leases	188,558
Long-term lease obligations	$ 925,386

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases
Increase in right-of-use asset	$ 977,220
Initial lease liability	15,000
Lease payments	14,181
Operating lease amortization expense	132,847	$ 97,436
Payment for operating lease liabilities	$ 120,403	$ 96,954

SCHEDULE OF BUSINESS INTERESTS

SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 2,400,311			$ 2,550,046			$ 8,919,312	$ 7,501,535
Gross Profit	1,401,991			1,281,041			3,908,608	3,505,743
Segment Assets	4,689,261			5,514,101			4,689,261	5,514,101	$ 5,766,164
Segment Profit/Loss	(528,742)	$ (1,112,261)	$ (965,836)	(1,301,748)	$ (2,578,276)	$ (651,519)	(2,606,839)	(4,531,543)
Cost of Sales							5,010,704	3,995,792
Trxade, Inc.[Member]
Segment Reporting Information [Line Items]
Revenue							4,001,670	3,653,269
Gross Profit							4,001,670	3,652,015
Segment Assets	1,853,474			1,487,657			1,853,474	1,487,657
Segment Profit/Loss							1,320,138	1,511,809
Cost of Sales								1,254
Community Specialty Pharmacy, LLC [Member]
Segment Reporting Information [Line Items]
Revenue							905,083	1,287,296
Gross Profit							(114,387)	123,470
Segment Assets	236,827			(404,174)			236,827	(404,174)
Segment Profit/Loss							(363,212)	(89,025)
Cost of Sales							1,019,470	1,163,826
Integra Pharma, LLC [Member]
Segment Reporting Information [Line Items]
Revenue							3,949,772	2,511,270
Gross Profit							(41,462)	(319,104)
Segment Assets	454,783			563,396			454,783	563,396
Segment Profit/Loss							(493,203)	(2,500,032)
Cost of Sales							3,991,234	2,830,374
Other Segments [Member]
Segment Reporting Information [Line Items]
Revenue							62,787	49,700
Gross Profit							62,787	49,362
Segment Assets	$ 2,111,177			$ 3,867,221			2,111,177	3,867,221
Segment Profit/Loss							(3,070,562)	(3,454,295)
Cost of Sales								$ 338

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 04, 2022	Sep. 30, 2022	Jul. 29, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Common stock, par value		$ 0.00001				$ 0.00001
Stockholders equity		$ 1,356,578		$ 1,804,533	$ 2,887,578	$ 3,770,173	$ 4,617,295	$ 5,786,977	$ 8,201,624	$ 8,679,158
Minimum [Member] | The Nasday Stock Market L L C [Member]
Subsequent Event [Line Items]
Stockholders equity			$ 2,500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock issued during period shares new issues	920,000
Common stock, par value	$ 0.00001
Warrants price per share	$ 1.15
Percentage of common stock outstanding	4.99%
Warrants percentage description	the Company subject to the terms of such warrants, provided that such percentage may in no event exceed 9.99%, and provided further that the Purchaser has elected to increase the ownership limitation to 9.99% in connection with the initial issuance of the Pre-Funded Warrants
Percentage of issued and outstanding common stock	19.99%
Proceeds from issuance of warrants	$ 1,750,000
Proceeds from company offering	$ 1,500,000
Subsequent Event [Member] | Placement Agent Agreement [Member]
Subsequent Event [Line Items]
Percentage of cash fee	7%
Warrants and reimbursed expense	$ 35,000
Subsequent Event [Member] | Private Placement Warrants [Member]
Subsequent Event [Line Items]
Common stock, par value	2,663,045
Subsequent Event [Member] | Pre Funded Warrants [Member]
Subsequent Event [Line Items]
Common stock, par value	601,740
Warrants price per share	$ 1.14999